Retigabine: A novel anticonvulsant drug

Indian Journal of Pharmacology

Volumn 37, Issue 5, 2005, Pages 340-341

  Anand, I S ^a   Shah, J S ^a   Patel, S K ^a   Patel, C N ^a  

^a Shri Sarvajanik Pharmacy College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBON 14; RETIGABINE; VOLTAGE GATED POTASSIUM CHANNEL;

ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ASTHENIA; CHILL; CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TOLERANCE; EPILEPSY; GABAERGIC TRANSMISSION; HEADACHE; HUMAN; HYPOTENSION; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; PAIN; SEIZURE; SEX DIFFERENCE; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; VOMITING; WITHDRAWAL SYNDROME;

EID: 26444581242     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: 10.4103/0253-7613.16866     Document Type: Short Survey

References (19)

1. + channels in neuronal cells. Eur J Clin Pharmacol 1997;336:243-249.
2. Meisel P, Landgraf K-F, Schafer J, Thiel W, Rischer W, Olbrich A, et al. US Patent (5,914,425) 1999.
3. Wuttke T, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant Retigabine favors voltage-dependent opening of Kv7.2(KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17.
4. Rundfelt C, Netzer R. Investigations into mechanism of action of new anticonvulsant. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000;50:1063-70.
5. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Emanuele E, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23.
6. Tober C, Rostock A, Rundfeldt C, Bartsh R. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-9.
7. Blackburn-Munro G, Skaning Jensen B. The anticonvulsant retigabine attenuates nociceptive behaviours in animal models of persistent and neuropathic pain. Eur J Pharmacol 2003;460:109-16.
8. Dost R, Rostock A, Rundfeldt C. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedeberds Arch Pharmacol 2004;369:382-90.
9. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterization of acid-induced muscle allodynia in rats. Eur J Pharmacol 2004;487:93-103.
10. Njung'e K, Handley SL. Evaluation of marble-burying behaviour as a model of anxiety. Pharmacol Biochem Behav 1991;38:63-7.
11. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterization of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology 1994;116:56-64.
12. Hermann R, Ferron GM, Erb K, Knebel N, Ruus P, Paul J, et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003;73:61-70.
13. Hempel R, Schupke H, McNeilly PJ, Heinecke K, Kronbach C, Grunwald C, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-22.
14. McNrilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg JH, Strong JM. In vitro glucuronidation of D-2319, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-41.
15. Friedel HA, Fitton A. Flupitrine. A review of its pharmacological properties and therapeutic efficacy in pain states. Drugs 1993;45:548-69.
16. Hermann R, Knebel NG, Neibch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003;58:795-802.
17. De Sarro G, Di Paola ED, Conte G, Pasculli MP, De Sarro A. Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice. Naunyn Schmiedebergs Arch Pharmacol 2001;363:330-6.
18. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Gesty J, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-182.
19. Wuttke T, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of Kv7.2(KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-17.